SHANGHAI and NANJING, China and PLEASANTON, Calif., March 24, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for...
Hence then, the article about iaso bio has received clearance from japan s pmda to initiate clinical trial for car t therapy equecabtagene autoleucel in second or third line multiple myeloma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( IASO Bio Has Received Clearance from Japan's PMDA to Initiate Clinical Trial for CAR-T Therapy Equecabtagene Autoleucel in Second- or Third-Line Multiple Myeloma )
Also on site :
- TrustNordisk Unveils Fresh Deals & Teaser-Trailer For Venice Contender ‘Woman Unknown’
- Quote of the Day: Philosopher Socrates on ‘An Eye for an Eye’ Mentality— ‘One Should Never Do Wrong in Return…’
- 1986 ‘Talk Dirty to Me,’ Recorded by Poison in Just 12 Days for $23,000 and Called a ‘Glorified Demo,’ Hit the Top 10 and Never Left